Tempus AI's CEO Sold $6.6 Million in Stock the Day Before a Huge Rally. Here's What to KnowThe Motley Fool • 08/22/26
Tempus AI Just Had Their Entire Strategy Validated By Moderna's Vaccine AdvanceSeeking Alpha • 08/20/26
Moderna's Cancer Breakthrough Just Made Tempus AI's $1.5 Billion Bet Look Brilliant24/7 Wall Street • 08/19/26
Tempus AI's FDA Win Could Unlock Major Reimbursement Growth AheadZacks Investment Research • 08/13/26
Is Tempus AI Worth Buying as Growth Improves but Valuation Stays High?Zacks Investment Research • 08/12/26
Tempus Q2 Earnings Call Highlights Data Growth and Pricing UpsideZacks Investment Research • 08/11/26
Tempus Study Published in Nature Medicine Demonstrates Best-in-Class Performance of PRISM2 Across Diagnostic and Prognostic ApplicationsBusiness Wire • 08/04/26
PERSONALIS SHAREHOLDER ALERT: PSNL Shareholders Interested in Pursuing Potential Claims Should Contact Julie & Holleman Regarding Proposed Sale to TempusGlobeNewsWire • 08/03/26
Compared to Estimates, Tempus (TEM) Q2 Earnings: A Look at Key MetricsZacks Investment Research • 07/30/26
Tempus AI Stock Before Q2 Earnings Release: To Buy, Hold or Sell?Zacks Investment Research • 07/24/26
Tempus AI (TEM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 ReleaseZacks Investment Research • 07/23/26
Tempus Announces National Launch of OneOme Pharmacogenomics Testing, Advancing Patient Safety and Precision MedicineBusiness Wire • 07/22/26
Personalis Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Personalis, Inc. - PSNLBusiness Wire • 07/21/26
Cathie Wood's Tempus AI Bet Is Bleeding — And the Chart Looks Worse Than Wall Street ThinksBenzinga • 07/20/26